Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

657 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vein wall thickness and severity of pulmonary involvement due to sars n-cov2 virus infection.
Quarto G, Benassai G, Colao A, Cittadini A, Ascierto PA, Pivonello R, Elefante A, Bocchino M, Marra AM, Gentile I, Benassai G, Miletti A, Calemma F, Furino E; members of FACTA study group. Quarto G, et al. Among authors: ascierto pa. J Transl Med. 2024 Jan 17;22(1):70. doi: 10.1186/s12967-024-04857-w. J Transl Med. 2024. PMID: 38233934 Free PMC article.
Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology.
Quagliariello V, Passariello M, Bisceglia I, Paccone A, Inno A, Maurea C, Rapuano Lembo R, Manna L, Iovine M, Canale ML, Scherillo M, Ascierto PA, Gabrielli D, De Lorenzo C, Maurea N. Quagliariello V, et al. Among authors: ascierto pa. Front Cardiovasc Med. 2024 Jan 23;11:1232269. doi: 10.3389/fcvm.2024.1232269. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38322766 Free PMC article.
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
Perrone F, Piccirillo MC, Ascierto PA, Salvarani C, Parrella R, Marata AM, Popoli P, Ferraris L, Marrocco-Trischitta MM, Ripamonti D, Binda F, Bonfanti P, Squillace N, Castelli F, Muiesan ML, Lichtner M, Calzetti C, Salerno ND, Atripaldi L, Cascella M, Costantini M, Dolci G, Facciolongo NC, Fraganza F, Massari M, Montesarchio V, Mussini C, Negri EA, Botti G, Cardone C, Gargiulo P, Gravina A, Schettino C, Arenare L, Chiodini P, Gallo C; TOCIVID-19 investigators, Italy. Perrone F, et al. Among authors: ascierto pa. J Transl Med. 2020 Oct 21;18(1):405. doi: 10.1186/s12967-020-02573-9. J Transl Med. 2020. PMID: 33087150 Free PMC article. Clinical Trial.
Cost of illness del carcinoma cutaneo a cellule squamose (CSCC).
Marcellusi A, Bini C, Peris K, Ascierto PA, Mennini FS. Marcellusi A, et al. Among authors: ascierto pa. Glob Reg Health Technol Assess. 2020 Dec 28;7:148-153. doi: 10.33393/grhta.2020.2171. eCollection 2020 Jan-Dec. Glob Reg Health Technol Assess. 2020. PMID: 36627959 Free PMC article. Italian.
Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness.
Mannino M, Piccerillo A, Fabbrocini G, Quaglino P, Argenziano G, Dika E, Ascierto PA, Pellacani G, Longo C, Fargnoli MC, Bianchi L, Calzavara-Pinton P, Zalaudek I, Fava P, Scalvenzi M, Bocchino E, Di Stefani A, Peris K; and Collaborators. Mannino M, et al. Among authors: ascierto pa. Dermatology. 2023;239(6):868-876. doi: 10.1159/000531280. Epub 2023 Jun 13. Dermatology. 2023. PMID: 37311439
POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis.
Menzies AM, Long GV, Kohn A, Tawbi H, Weber J, Flaherty K, McArthur GA, Ascierto PA, Pfluger Y, Lewis K, Tsai KK, Hamid O, Prenen H, Fein L, Wang E, Guenzel C, Zhang F, Kleha JF, di Pietro A, Davies MA. Menzies AM, et al. Among authors: ascierto pa. Neurooncol Adv. 2024 Mar 18;6(1):vdae033. doi: 10.1093/noajnl/vdae033. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38725995 Free PMC article.
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
Schadendorf D, Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liszkay G, Loquai C, Mandalà M, Yamazaki N, Queirolo P, Guenzel C, Polli A, Thakur M, di Pietro A, Ascierto PA. Schadendorf D, et al. Among authors: ascierto pa. Eur J Cancer. 2024 Jun;204:114073. doi: 10.1016/j.ejca.2024.114073. Epub 2024 Apr 24. Eur J Cancer. 2024. PMID: 38723373 Free article. Clinical Trial.
657 results